Chemically targeting the PI3K family.

PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metabolism and survival. The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms. The present paper highlights recent progress in identifying such molecules and the challenges that remain for efforts to pharmacologically target the PI3K family.

[1]  M. Waterfield,et al.  Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors , 2007 .

[2]  Anthony C. Bishop,et al.  Structural basis for selective inhibition of Src family kinases by PP1. , 1999, Chemistry & biology.

[3]  S. Jackson,et al.  Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase , 2005, Nature Cell Biology.

[4]  J. Rohn,et al.  Gene Targeting Attention to Detail , 2004, Cell.

[5]  I. Hardcastle,et al.  Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. , 2004, Bioorganic & medicinal chemistry letters.

[6]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[7]  I. Hardcastle,et al.  Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. , 2005, Journal of medicinal chemistry.

[8]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[9]  M. Baggiolini,et al.  Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. , 1987, Experimental cell research.

[10]  Kevan M Shokat,et al.  Targeting the gatekeeper residue in phosphoinositide 3-kinases. , 2005, Bioorganic & medicinal chemistry.

[11]  J. Kuriyan,et al.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.

[12]  M. Waterfield,et al.  Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.

[13]  N. Curtin,et al.  Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. , 2005, Journal of medicinal chemistry.

[14]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[15]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[17]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[18]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[19]  A. Robertson,et al.  PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.

[20]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[21]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[22]  Peter J. Alaimo,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. , 2004, Bioorganic & medicinal chemistry.

[23]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[24]  D. Staunton,et al.  Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement , 2003, The Journal of Immunology.

[25]  J. Schiro,et al.  DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. , 2003, Molecular cancer therapeutics.

[26]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[27]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[28]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[29]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[30]  B. Park,et al.  Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.